Mary Beth Fritz, Senior Vice President of Quality & Regulatory at Prestige Consumer Healthcare Inc. (NYSE:PBH), recently executed a series of stock transactions, according to a Form 4 filing with the Securities and Exchange Commission. On November 12, Fritz sold a total of 9,885 shares of Prestige Consumer Healthcare common stock, with prices ranging from $81.93 to $81.99 per share. The transactions amounted to a total value of $810,266.
In addition to these sales, Fritz acquired a total of 9,885 shares through stock options at prices between $39.98 and $54.47 per share, totaling $444,671. Following these transactions, Fritz holds 18,835 shares directly.
In other recent news, Prestige Consumer Healthcare announced mixed results in their Q2 earnings call. The company reported a slight dip in sales, landing at $284 million for the quarter, despite an increase in earnings per share to $1.09 and a free cash flow of $68 million. This was largely due to supply chain issues with the Clear Eyes brand, although international growth, particularly with the Hydralyte brand and Canadian portfolio, helped balance the decrease.
Prestige Consumer Healthcare also provided fiscal year revenue guidance, estimating between $1.125 billion and $1.140 billion, and an adjusted EPS forecast of $4.40 to $4.46. Additionally, the company managed to reduce debt by $40 million, achieving a leverage ratio of 2.7x. E-commerce, which currently makes up 15% of revenue, is also set for international expansion.
These recent developments illustrate the company's commitment to capital deployment, including share repurchases and potential mergers and acquisitions. Despite certain challenges, Prestige Consumer Healthcare remains optimistic about its ability to navigate current issues and capitalize on growth opportunities.
InvestingPro Insights
Recent data from InvestingPro sheds additional light on Prestige Consumer Healthcare Inc.'s (NYSE:PBH) financial position and market performance. The company's stock has shown strong momentum, with a 16.2% return over the past month and a 20.53% return over the last three months. This aligns with the recent insider transaction activity, potentially indicating positive sentiment within the company's leadership.
InvestingPro data reveals that Prestige Consumer Healthcare has a market capitalization of $4.09 billion and a P/E ratio of 19.9, suggesting a relatively moderate valuation compared to some industry peers. The company's revenue for the last twelve months stands at $1.11 billion, with a robust gross profit margin of 56.01%.
Two key InvestingPro Tips are particularly relevant to the recent insider activity:
1. The stock is trading near its 52-week high, which could explain the timing of Mary Beth Fritz's decision to sell shares.
2. Prestige Consumer Healthcare has a high shareholder yield, indicating that the company is returning value to shareholders through various means.
These insights provide context for the insider's transactions and the company's overall financial health. InvestingPro offers 9 additional tips for Prestige Consumer Healthcare, providing a more comprehensive analysis for investors interested in delving deeper into the company's prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.